---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-24-000002"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:02:05.785581+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Novocure appoints Dr. Nicolas Leupin as CMO; Pritesh Shah steps down as executive officer

## Summary
- Dr. Nicolas Leupin appointed CMO, overseeing medical affairs, safety, and clinical development.
- Pritesh Shah resigns as executive officer; to serve as Senior Advisor to CEO through June 30, 2025.
- Frank Leonard appointed EVP and President, Novocure Oncology; base salary $525,000, target bonus 60%.
- Shah's salary drops from $500k to $120k after June 2024; equity grants continue vesting.

## SEC filing metadata
- accession: 0001645113-24-000002
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/nvcr-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-24-000002
- JSON: https://secwatch.observer/filing/0001645113-24-000002.json
- Plain text: https://secwatch.observer/filing/0001645113-24-000002.txt

## Key facts
- Executive change
  Pritesh Shah resigned as Chief Growth Officer at NovoCure Ltd.
  - Action: resigned
  - Role: Chief Growth Officer
  source text: Effective January 1, 2024, Pritesh Shah, Chief Growth Officer of the Company, resigned his position as an executive officer of the Company and agreed to become a Senior Advisor to the Chief Executive Officer, a non-executive position.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm
- Executive change
  Frank Leonard was appointed as Executive Vice President and President, Novocure Oncology at NovoCure Ltd.
  - Action: appointed
  - Role: Executive Vice President and President, Novocure Oncology
  source text: Effective January 1, 2024, the Company appointed Frank Leonard, Executive Vice President and President, Novocure Oncology.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645113/000164511324000002/0001645113-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.